tbuckley/cabot-search huggingface dataset:
AB0320 Rheumatoid arthritis in brazil – the “real” study: a nationwide prospective study
Authors: G Castelar-Pinheiro, AB Vargas-Santos, C Albuquerque, R Amorim, R Giorgi, S Radominski, I Pereira, MF Guimarães, M Bértolo, P Louzada, MF Cunha, K Bonfiglioli, C Brenol, LMH Mota
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Early diagnosis and immediate treatment are critical in achieving optimal outcomes in rheumatoid arthritis (RA). However, anecdotal evidence suggests that in Brazil there is still a significant delay in patient referral, RA diagnosis and DMARD initiation. The lack of national data hinders effective advocacy for proper public health policies, which led the RA commission of the Brazilian Society of Rheumatology to create a nationally-representative multicenter RA cohort to provide the necessary data. <h3>Objectives</h3> To describe the development process and baseline characteristics of a large, nationally-representative multicenter cohort of RA patients in Brazil. <h3>Methods</h3> Eleven public rheumatology centers from all of the 5 regions of Brazil enrolled ∼100 consecutive RA patients each (1987 ARA or 2010 ACR-EULAR). This cohort is being followed prospectively for 1 year, with systematic data collection at time 0, 6±1 months and 12±1 months, and registration of all other visits during this 1-year period. Data collection began in 08–2015, using a single online electronic medical record, and included demographic, socioeconomic, clinical, lab, radiographic and therapeutic characteristics, along with functional status, quality of life and adherence to treatment information. <h3>Results</h3> 1125 patients were enrolled (Table), ∼90% were female, with a mean age of 56 years and median disease duration of 13 years. Median BMI was 27 kg/m<sup>2</sup>, with 64% of the patients classified as overweight or obese. The interval between symptoms and diagnosis varied from 1 to 457 months (median 12 months). Almost half of the patients were on glucocorticoids, 96% on DMARDs, with 36% on biologics. Only 7% were seronegative for both rheumatoid factor and ACPA. Median HAQ-DI was 0.875 and median DAS28-ESR was 3.5, with 58.6% of patients presenting moderate or high disease activity. <h3>Conclusions</h3> The delay in diagnosis may explain the high percentage of patients with moderate or high disease activity and erosive disease. The low level of physical dysfunction observed in this established, predominantly seropositive RA population may be explained by the large proportion of patients on glucocorticoid and biologic therapy. Our findings suggest that, despite current treatment concepts being well known and accepted by Brazilian rheumatologists, there is still a gap in early diagnosis and management of RA. <h3>Disclosure of Interest</h3> None declared
Niraparib therapy in patients with newly diagnosed advanced ovarian cancer (PRIMA/ENGOT-OV26/GOG-3012 study)
Authors: A. González Martín, B. Pothuri, I.B. Vergote, R.D. Christensen, W. Graybill, M.R. Mirza, C. McCormick, D. Lorusso, P. Hoskins, G. Freyer, F. Backes, K. Baumann, A. Redondo, R.G. Moore, C. Vulsteke, R.E. O’Cearbhaill, B. Lund, Y. Li, D. Gupta, B.J. Monk
Journal: Annals of Oncology (2019)
定期的に透析治療(RDT)を受ける患者の高血圧に対する、欠陥的L‐アルギニン一酸化窒素(NO)経路の役割
Authors: Nakayama M, Hasegawa T, Kubo H, Shigematu T, Kawaguchi Y, Sakai O
Journal: Journal of the American Society of Nephrology (1994)
Estrogen and Spermatogenesis*
Authors: Liza O’Donnell, Kirsten M. Robertson, Margaret E. Jones, Evan R. Simpson
Journal: Endocrine Reviews (2001)

Although it has been known for many years that estrogen administration has deleterious effects on male fertility, data from transgenic mice deficient in estrogen receptors or aromatase point to an essential physiological role for estrogen in male fertility. This review summarizes the current knowledge on the localization of estrogen receptors and aromatase in the testis in an effort to understand the likely sites of estrogen action. The review also discusses the many studies that have used models employing the administration of estrogenic substances to show that male fertility is responsive to estrogen, thus providing a mechanism by which inappropriate exposure to estrogenic substances may cause adverse effects on spermatogenesis and male fertility. The reproductive phenotypes of mice deficient in estrogen receptors alpha and/or beta and aromatase are also compared to evaluate the physiological role of estrogen in male fertility. The review focuses on the effects of estrogen administration or deprivation, primarily in rodents, on the hypothalamo-pituitary-testis axis, testicular function (including Leydig cell, Sertoli cell, and germ cell development and function), and in the development and function of the efferent ductules and epididymis. The requirement for estrogen in normal male sexual behavior is also reviewed, along with the somewhat limited data on the fertility of men who lack either the capacity to produce or respond to estrogen. This review highlights the ability of exogenous estrogen exposure to perturb spermatogenesis and male fertility, as well as the emerging physiological role of estrogens in male fertility, suggesting that, in this local context, estrogenic substances should also be considered "male hormones."
Preliminary safety and pharmacokinetics of a new lysosomotropic oral agent, GNS561, in a first-in-human study in advanced primary liver cancer patients
Authors: A.H. Awada, J.J. Harding, N. Kotecki, P.G. Aftimos, T. Decaens, C. Dreyer, C. Ansaldi, M. Rachid, C. Serdjebi, P. Halfon, G.K. Abou-Alfa, E. Raymond
Journal: Annals of Oncology (2019)
Limiting the Number of Open Records in an Electronic Health Record—Reply
Authors: Jason S. Adelman, Jo R. Applebaum, William N. Southern
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Perioperative chemotherapy with docetaxel, oxaliplatin, fluorouracil and leucovorin (FLOT) versus epirubicin, platinum and capecitabine or flourouracil (EOX/ECF) in resectable gastric or gastroesophageal junction adenocarcinoma: Safety and response data from India
Authors: T. Chawla, R. Thambudorai, A. Ashok, B. Roy, J. Ghosh, S. Ganguly, P. Roy, M. Mallath
Journal: Annals of Oncology (2019)
Talking about Toxicity — “What We’ve Got Here Is a Failure to Communicate”
Authors: Chana A. Sacks, Pamela W. Miller, Dan L. Longo
Journal: New England Journal of Medicine (2019)

Improving communication with patients about treatment risks and benefits has long been recognized as a critical priority. But perhaps a necessary first step is for investigators to communicate with clinicians openly and specifically about the toxic effects of treatment.
Drinking alcohol, smoking, multiple dysplastic lesions and the risk of field cancerization of squamous cell carcinoma in the esophagus and head and neck region
Authors: C. Katada, T. Yokoyama, T. Yano, I. Oda, Y. Shimizu, H. Doyama, T. Koike, K. Takizawa, M. Hirao, H. Okada, H. Ishikawa, A. Yokoyama, M. Muto
Journal: Annals of Oncology (2019)
Autologous Stem Cell Transplantation with Yttriumm-90-Ibritumomab Tiuxetan (Zevalin) Plus BEAM Conditioning in Patients with Refractory Non-Hodgkin Diffuse Large B-Cell Lymphoma: Results of a Prospective, Multicenter, Phase II Clinical Trial
Authors: Javier Briones, Silvana Novelli, Jose Antonio Garcia Marco, Jose Francisco Tomas, Teresa Bernal, Carlos Grande, Miguel Canales, Antonio Torres, José M. Moraleda, Carlos Panizo, Fernanda Palmero, Isidro Jarque, Miguel Hernandez, Eva Gonzalez Barca, Dulce Lopez, Dolores Caballero
Journal: Blood (2012)
68Ga-PSMA guided bone biopsies for molecular diagnostics in metastatic castration resistant prostate cancer patients
Authors: A.C. de Jong, M. Segbers, M. Smits, T. Brabander, R. de Wit, N. Mehra, A.A.M. Van der Veldt, M.P. Lolkema
Journal: Annals of Oncology (2019)
Pathological transition as the arising mechanism for drug resistance in lung cancer
Authors: Yueqing Chen, Waiying Yvonne Tang, Xinyuan Tong, Hongbin Ji
Journal: Cancer Communications (2019)

Abstract Despite the tremendous efforts for improving therapeutics of lung cancer patients, its prognosis remains disappointing. This can be largely attributed to the lack of comprehensive understanding of drug resistance leading to insufficient development of effective therapeutics in clinic. Based on the current progresses of lung cancer research, we classify drug resistance mechanisms into three different levels: molecular, cellular and pathological level. All these three levels have significantly contributed to the acquisition and evolution of drug resistance in clinic. Our understanding on drug resistance mechanisms has begun to change the way of clinical practice and improve patient prognosis. In this review, we focus on discussing the pathological changes linking to drug resistance as this has been largely overlooked in the past decades.
Adjuvant Chemotherapy in Patients with Neuroendocrine Carcinoma of the Urinary Tract
Authors: Hiromichi Nakajima, Chihiro Kondoh, Yukinori Ozaki, Yuko Tanabe, Yuji Miura, Kazushiige Sakaguchi, Shinji Uragami, Naoko Inoshita, Toshikazu Okaneya, Toshimi Takano
Journal: Annals of Oncology (2017)
Accuracy of pathologic evaluation for thymic epithelial tumors in an Italian reference centre
Authors: G. Galli, A. Fabbri, R. Ferrara, A. Prelaj, C. Proto, D. Signorelli, A. De Toma, F. Pagani, N. Zilembo, M. Ganzinelli, G. Pruneri, F.G.M. de Braud, M.C. Garassino, G. Lo Russo
Journal: Annals of Oncology (2019)
Proximal tubule ATR regulates DNA repair to prevent maladaptive renal injury responses
Authors: Seiji Kishi, Craig R. Brooks, Kensei Taguchi, Takaharu Ichimura, Yutaro Mori, Akinwande Akinfolarin, Navin Gupta, Pierre Galichon, Bertha C. Elias, Tomohisa Suzuki, Qian Wang, Leslie Gewin, Ryuji Morizane, Joseph V. Bonventre
Journal: Journal of Clinical Investigation (2019)

Maladaptive proximal tubule (PT) repair has been implicated in kidney fibrosis through induction of cell-cycle arrest at G2/M. We explored the relative importance of the PT DNA damage response (DDR) in kidney fibrosis by genetically inactivating ataxia telangiectasia and Rad3-related (ATR), which is a sensor and upstream initiator of the DDR. In human chronic kidney disease, ATR expression inversely correlates with DNA damage. ATR was upregulated in approximately 70% of Lotus tetragonolobus lectin-positive (LTL+) PT cells in cisplatin-exposed human kidney organoids. Inhibition of ATR resulted in greater PT cell injury in organoids and cultured PT cells. PT-specific Atr-knockout (ATRRPTC-/-) mice exhibited greater kidney function impairment, DNA damage, and fibrosis than did WT mice in response to kidney injury induced by either cisplatin, bilateral ischemia-reperfusion, or unilateral ureteral obstruction. ATRRPTC-/- mice had more cells in the G2/M phase after injury than did WT mice after similar treatments. In conclusion, PT ATR activation is a key component of the DDR, which confers a protective effect mitigating the maladaptive repair and consequent fibrosis that follow kidney injury.
Early prediction of the platinum-resistant relapse risk using the CA125 modeled kinetic parameter KELIM: A pooled analysis of AGO-OVAR 7 &amp; 9; ICON 7 (AGO/GINECO/ MRC CTU/GCIG trials)
Authors: O. Colomban, M. Tod, A. Leary, I.L. Ray-Coquard, A. Lortholary, A.-C. Hardy-Bessard, J. Pfisterer, A. Du Bois, C. Kurzeder, A. Burges, J. Peron, G. Freyer, B. You
Journal: Annals of Oncology (2019)
Abstract 2688: ZB716 is orally efficacious in blocking tumor growth in mouse xenograft models
Authors: Shanchun Guo, Changde Zhang, Jiawang Liu, Shilong Zheng, Lin Yang, Guangdi Wang
Journal: Cancer Research (2018)

Abstract Advances in oral SERDs development so far have been confined to nonsteroidal molecules such as those containing a cinnamic acid moiety, which are in early-stage clinical evaluation. ZB716 was previously reported as an orally bioavailable SERD structurally analogous to fulvestrant. In this study, we examined the binding details of ZB716 to the estrogen receptor alpha (ERα) by computer modeling to reveal its interactions with the ligand binding domain as a steroidal molecule. The ability of ZB716 to inhibit cell growth and downregulate ER expression in endocrine resistant, ERα mutant breast cancer cells was demonstrated. Moreover, in the MCF-7 xenograft and two patient derived xenograft models, orally administered ZB716 showed superior efficacy in blocking tumor growth when compared to fulvestrant. Importantly, such enhanced efficacy of ZB716 was shown to be attributable to its markedly higher bioavailability, as evidenced in the final plasma and tumor tissue concentrations of ZB716 in mice where drug concentrations were found significantly higher than in the fulvestrant treatment group. Citation Format: Shanchun Guo, Changde Zhang, Jiawang Liu, Shilong Zheng, Lin Yang, Guangdi Wang. ZB716 is orally efficacious in blocking tumor growth in mouse xenograft models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2688.
Impact of neurological symptom burden on the survival prognosis in a real-life cohort of patients with non-small cell lung cancer brain metastases
Authors: A. Steindl, S. Yadavalli, K.A. Gruber, M. Seiwald, J.M. Frischer, B. Gatterbauer, K. Dieckmann, C. Marosi, G. Widhalm, M. Preusser, A.S. Berghoff
Journal: Annals of Oncology (2019)
Inferring the correlation between incidence rates of melanoma and the average tumour-specific epitope binding ability of HLA class I molecules in different populations
Authors: I. Miklos, L. Molnar, J. Toth, O. Lorincz, Z. Csiszovszki, P. Pales, K. Pántya, M. Megyesi, E. Somogyi, E.R. Tőke
Journal: Annals of Oncology (2019)
RAS mutant allele fraction in plasma predicts benefit to anti-angiogenic based first-line treatment in metastatic colorectal cancer
Authors: G. Martini, E. Elez, F.M. Mancuso, M A Gomez España, G. Caratù, J. Matito, G Argiles Martinez, N Mulet Margalef, M J Ortiz Morales, F J Ros Montana, A. Garcia, R. Comas, C Santos Vivas, R. Perez-Lopez, P.G. Nuciforo, O. Casanovas, R. Dienstmann, J. Tabernero, E Aranda Aguilar, A. Vivancos
Journal: Annals of Oncology (2019)
Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration
Authors: J. Taieb, V. Taly, D. Vernerey, C. Bourreau, J. Bennouna, R. Faroux, J. Desrame, O. Bouche, C. Borg, J. Egreteau, L. Mineur, C. Lepere, G. Deplanque, C. Mulot, C. Louvet, M. Mabro, M. Ychou, A. de Gramont, T. Andre, P. Laurent-Puig
Journal: Annals of Oncology (2019)
Randomized phase II trial evaluating the safety of peripherally inserted central catheters vs implanted port catheters during adjuvant chemotherapy in early breast cancer patients
Authors: F. Clatot, M. Fontanilles, L. Lefebvre, J. Lequesne, C. Veyret, C. Alexandru, M. Leheurteur, C. Guillemet, S. Gouérant, C. Petrau, J.-C. Thery, O. Rigal, C. Moldovan, I. Tennevet Bouilly, O. Rastelli, M. Bubenheim, D. Georgescu, J. Gouérant, M. Gilles-Baray, F. Di Fiore
Journal: Annals of Oncology (2019)
Outcome of triple negative inflammatory breast cancers (TNIBC) treated with dose dense neoadjuvant epirubicin cyclophosphmide, prognostic impact of pre and post neoadjuvant chemotherapy (NAC) tumour infiltrating lymphocytes (TIL) and post NAC lymphovascular invasion
Authors: L. Campedel, P. Blanc-Durand, A. Binasker, S. Bécourt, F. Ledoux, C. Cuvier, C. Gardair, L. Teixeira, A. De Roquancourt, J. Lehmann Che, M. Espié, S. Giacchetti
Journal: Annals of Oncology (2019)
A phase I study of Ad5 PSA/MUC-1/brachyury vaccine in patients with metastatic castration resistant prostate cancer (mCRPC)
Authors: M. Bilusic, R.A. Madan, F.H. Karzai, S. McMahon, R.N. Donahue, J. Strauss, M.E. Gatti-Mays, J. Redman, L.M. Cordes, C. Palena, E.S. Gabitzsch, F.R. Jones, J.P. Balint, P. Soon-Shiong, S. Rabizadeh, M. Policard, J. Schlom, J.L. Gulley
Journal: Annals of Oncology (2019)
Effect of Tight Control of Blood Glucose during Hyper-CVAD Chemotherapy for Acute Lymphocytic Leukemia.
Authors: Khanh Vu, Sai-Ching Yeung, Deborah A. Thomas, Stefan Faderl, Marina Konopleva, Naifa Busaidy, Maria Cabanillas, Dushyant Verma, Carmen Escalante, Susan O’Brien, Victor Lavis, Hagop Kantarjian, Mary Ann Weiser
Journal: Blood (2008)
Matrix metalloproteinases and their tissue inhibitors genes abnormal DNA methylation in breast cancer
Authors: O. Simonova, E. Kuznetsova, A.S. Tanas, V. Rudenko, E. Poddubskaya, T. Kekeeva, G. Chesnokova, S. Kutsev, D.V. Zaletaev, M.V. Nemtsova, V.V. Strelnikov
Journal: Annals of Oncology (2019)
Normalization of Tumor Vasculature by Oxygen Microbubbles with Ultrasound
Authors: Yi-Ju Ho, Shu-Wei Chu, En-Chi Liao, Ching-Hsiang Fan, Hong-Lin Chan, Kuo-Chen Wei, Chih-Kuang Yeh
Journal: Theranostics (2019)

Tumor microenvironment influences the efficacy of anti-cancer therapies.The dysfunctional tumor vasculature limits the efficiency of oxygenation and drug delivery to reduce treatment outcome.A concept of tumor vascular normalization (VN), which inhibits angiogenesis to improve vessel maturity, blood perfusion, and oxygenation, has been demonstrated under the anti-angiogenic therapy.The efficiency of drug delivery and penetration is increased by enhancing perfusion and reducing interstitial fluid pressure during the time window of VN.However, anti-angiogenic agents only induce transient VN and then prune vessels to aggravate tumor hypoxia.To repair tumor vessels without altering vessel density, we proposed to induce tumor VN by local oxygen release via oxygen microbubbles with ultrasound.With tumor perfusion enhancement under ultrasound contrast imaging tracing, the time window of VN was defined as 2-8 days after a single oxygen microbubble treatment.The enhanced tumor oxygenation after oxygen microbubble treatment inhibited hypoxia inducible factor-1 alpha (HIF-1α)/vascular endothelial growth factor (VEGF) pathway to improve the morphology and function of tumor vasculature.The pericyte coverage and Hoechst penetration of tumor vessels increased without any changes to the vessel density.Finally, the intratumoral accumulation of anti-cancer drug doxorubicin could be increased 3-4 folds during tumor VN.These findings demonstrate that regulating tumor oxygenation by oxygen microbubbles could normalize dysfunctional vessels to enhance vascular maturity, blood perfusion, and drug penetration.Furthermore, ultrasound perfusion imaging provides a simple and non-invasive way to detect the VN time window, which increases the feasibility of VN in clinical cancer applications.
5α-Reductase Inhibitor Use in Patients With Prostate Cancer—Reply
Authors: Reith R. Sarkar, Brent S. Rose
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
PIK3CA mutation in metastatic colorectal cancer (mCRC): Association with clinico-pathological features and outcome
Authors: V. Fanotto, G. Zucchelli, M.M. Germani, D. Rossini, E. Sensi, C. Lupi, C. Ugolini, C. Antoniotti, F. Marmorino, R. Moretto, A. Boccaccino, B. Borelli, V. Conca, E. Ongaro, G. Masi, G. Fontanini, A. Falcone, C. Cremolini
Journal: Annals of Oncology (2019)
Registrational results of LOXO-292 in patients with RET-altered thyroid cancers
Authors: L. Wirth, E. Sherman, A. Drilon, B. Solomon, B. Robinson, J. Lorch, C. McCoach, J. Patel, S. Leboulleux, F. Worden, T. Owonikoko, M. Brose, M. Taylor, A. Italiano, O. Gautschi, M.-E. Garcia, S.M. Rothenberg, V. Subbiah, M. Shah, M. Cabanillas
Journal: Annals of Oncology (2019)
Avoiding Harm From Hyperbilirubinemia Screening
Authors: Jon F. Watchko, M. Jeffrey Maisels
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal